A real-world propensity analysis of the impact of GLP-1 receptor agonists on cancer therapy-related cardiac dysfunction.

Commun Med (Lond) · 2026 · PMC13324032 · PMID 42045526

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

showed a trendp = 0.060so close (0.05 < p ≤ 0.1)

In contrast, monoclonal antibody users did not experience a statistical difference (HR: 0.90; 95% CI: 0.76–1.05, p = 0.145), and notably, those using small molecule TKIs showed a trend toward increased risk with GLP1RA (HR: 1.23; 95% CI: 0.99–1.52, p = 0.060), although this was not statistically significant.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.